What does COVID-19 mean to our patients with multiple sclerosis?

Professor Gavin Giovannoni discusses the key issues and questions around COVID-19 for people with multiple sclerosis.

Over the last 5 years Professor Giovannoni has received personal compensation for participating on Advisory Boards in relation to multiple sclerosis clinical trial design, trial steering committees and data and safety monitoring committees from: Abbvie, Actelion, Atara Bio, Biogen-Idec, Celgene, Sanofi-Genzyme, Genentech, GSK, GW Pharma, Merck, Merck KGaA, Novartis, Roche and Teva. Professor Giovannoni is Co-Editor-in-Chief of Multiple Sclerosis and Related Disorders and chairs the MS Brain Health initiative, MS Academy and triMS.online conference. He has previously been a member of multiple sclerosis and related disorders specialist advisory group of the Association of British Neurologists and an ECTRIMS representative. He is a director of Oxford Health Policy Forum, a non-profit company.